Cargando…

Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results

Management of recurrent Hepatitis C virus (HCV) infection following liver transplantation remains a major challenge. In non-transplanted HCV genotype 1 patients, the introduction of protease inhibitor-based regimens has significantly increased the rate of sustained virological response. In this foll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Werner, Christoph R., Egetemeyr, Daniel P., Lauer, Ulrich M., Nadalin, Silvio, Königsrainer, Alfred, Malek, Nisar P., Berg, Christoph P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827217/ https://www.ncbi.nlm.nih.gov/pubmed/24265827 http://dx.doi.org/10.1371/journal.pone.0080528

Ejemplares similares

First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort
por: Werner, Christoph R, et al.
Publicado: (2015)

Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12
por: Werner, Christoph R, et al.
Publicado: (2016)

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021)

Right Hemihepatectomy by Suprahilar Intrahepatic Transection of the Right Hemipedicle using a Vascular Stapler
por: Königsrainer, Ingmar, et al.
Publicado: (2010)

Living donor liver transplantation with two-stage hepatectomy for patients with isolated, irresectable colorectal liver—the LIVER-T(W)O-HEAL study
por: Rauchfuß, Falk, et al.
Publicado: (2019)

Telaprevir
Publicado: (2012)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastases in Solid Organ Graft Recipients: First Experience
por: Horvath, Philipp, et al.
Publicado: (2019)

Diabetes Mellitus and Prediabetes on Kidney Transplant Waiting List- Prevalence, Metabolic Phenotyping and Risk Stratification Approach
por: Guthoff, Martina, et al.
Publicado: (2015)

A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma
por: Yurttas, Can, et al.
Publicado: (2021)

SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
por: Thorlund, Kristian, et al.
Publicado: (2014)

Analysis of the effects of the first and second/third waves of the COVID-19 pandemic on an Interdisciplinary Endoscopy Unit in a German ‘hotspot’ area: a single-center experience
por: Wichmann, Dörte, et al.
Publicado: (2022)

Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients
por: Abe, Hiroshi, et al.
Publicado: (2014)

Feasibility and outcome of spleen and vessel preserving total pancreatectomy (SVPTP) in pancreatic malignancies — a retrospective cohort study
por: Beltzer, Christian, et al.
Publicado: (2022)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Minimal-invasive management of urological complications after kidney transplantation
por: Deininger, Susanne, et al.
Publicado: (2021)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C
por: Kondo, C, et al.
Publicado: (2016)

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2013)

Telaprevir Experience From Turkey
por: Komur, Suheyla, et al.
Publicado: (2015)

Cutaneous Eruption due to Telaprevir
por: Falcão, Eduardo Mastrangelo Marinho, et al.
Publicado: (2015)

Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients
por: Guthoff, Martina, et al.
Publicado: (2020)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
por: Grottenthaler, Julia M., et al.
Publicado: (2018)

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
por: Bichoupan, Kian, et al.
Publicado: (2017)

Comment to “Telaprevir Experience From Turkey”
por: Akar, Tarik, et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

The Prevalence and Clinical Significance of Anaerobic Bacteria in Major Liver Resection
por: Strohäker, Jens, et al.
Publicado: (2021)

SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020
por: Quante, Markus, et al.
Publicado: (2021)

Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks
por: Tamai, Hideyuki, et al.
Publicado: (2014)

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
por: Hoffmann, Luísa, et al.
Publicado: (2015)

Sulphite oxidase (SO) – a mitochondrial autoantigen as target for humoral and cellular immune reactions in primary sclerosing cholangitis
por: Preuß, Beate E., et al.
Publicado: (2018)

Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study
por: Mangia, Alessandra, et al.
Publicado: (2017)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Safety and Tolerance of Donor-Derived Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation: The MYSTEP1 Study
por: Hartleif, Steffen, et al.
Publicado: (2017)

Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy
por: Neukam, Karin, et al.
Publicado: (2015)

Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin
por: Nakayama, Masahiko, et al.
Publicado: (2015)

Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhi
por: Akar, Tarık, et al.
Publicado: (2015)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Novel triple lumen catheter for ERCP tissue diagnosis
por: Goetz, Martin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lc8pi7qefds653hvufrlhiu6s4